Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Neuromyelitis Optica Spectrum Disorder (NMOSD) market report explains the definition, types, applications, major countries, and major players of the Neuromyelitis Optica Spectrum Disorder (NMOSD) market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Bio-Thera Solutions
Bionure
Boston Pharmaceuticals
RemeGen
Opexa Therapeutics
Nihon Pharmaceutical
Lundbeck
Harbour BioMed
TG Therapeutics
Alexion Pharmaceuticals
Cour Pharmaceutical
F Hoffmann-La Roche Ltd
By Type:
Intravenous
Oral
Subcutaneous
Others
By End-User:
Hospital
Clinic
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Outlook to 2028- Original Forecasts
-
2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market- Recent Developments
-
6.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market News and Developments
-
6.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Deals Landscape
7 Neuromyelitis Optica Spectrum Disorder (NMOSD) Raw Materials and Cost Structure Analysis
-
7.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Raw Materials
-
7.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Price Trend of Key Raw Materials
-
7.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Suppliers of Raw Materials
-
7.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Rate of Raw Materials
-
7.5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Cost Structure Analysis
-
7.5.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Raw Materials Analysis
-
7.5.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Labor Cost Analysis
-
7.5.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Manufacturing Expenses Analysis
8 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Import and Export Analysis (Top 10 Countries)
-
8.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Export by Region (Top 10 Countries) (2017-2028)
9 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook by Types and Applications to 2022
-
9.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Intravenous Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Oral Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Subcutaneous Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Analysis and Outlook till 2022
-
10.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.2.2 Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.2.3 Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.2 UK Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.3 Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.4 Belgium Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.5 France Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.6 Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.7 Denmark Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.8 Finland Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.9 Norway Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.10 Sweden Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.11 Poland Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.12 Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.3.13 Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.2 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.3 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.4 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.5 Pakistan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.6 Bangladesh Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.7 Indonesia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.8 Thailand Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.9 Singapore Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.10 Malaysia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.11 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.4.12 Vietnam Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.5.2 Colombia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.5.3 Chile Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.5.4 Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.5.5 Venezuela Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.5.6 Peru Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.5.7 Puerto Rico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.5.8 Ecuador Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.6.2 Kuwait Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.6.3 Oman Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.6.4 Qatar Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.6.5 Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.6.6 United Arab Emirates Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.7.2 South Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.7.3 Egypt Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.7.4 Algeria Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
-
10.8.2 New Zealand Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)
11 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Competitive Analysis
-
11.1 Bio-Thera Solutions
-
11.1.1 Bio-Thera Solutions Company Details
-
11.1.2 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.1.4 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Bionure
-
11.2.1 Bionure Company Details
-
11.2.2 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.2.4 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Boston Pharmaceuticals
-
11.3.1 Boston Pharmaceuticals Company Details
-
11.3.2 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.3.4 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 RemeGen
-
11.4.1 RemeGen Company Details
-
11.4.2 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.4.4 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Opexa Therapeutics
-
11.5.1 Opexa Therapeutics Company Details
-
11.5.2 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.5.4 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Nihon Pharmaceutical
-
11.6.1 Nihon Pharmaceutical Company Details
-
11.6.2 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.6.4 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Lundbeck
-
11.7.1 Lundbeck Company Details
-
11.7.2 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.7.4 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Harbour BioMed
-
11.8.1 Harbour BioMed Company Details
-
11.8.2 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.8.4 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 TG Therapeutics
-
11.9.1 TG Therapeutics Company Details
-
11.9.2 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.9.4 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Alexion Pharmaceuticals
-
11.10.1 Alexion Pharmaceuticals Company Details
-
11.10.2 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.10.4 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Cour Pharmaceutical
-
11.11.1 Cour Pharmaceutical Company Details
-
11.11.2 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.11.4 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 F Hoffmann-La Roche Ltd
-
11.12.1 F Hoffmann-La Roche Ltd Company Details
-
11.12.2 F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
11.12.4 F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
11.12.5 Recent Research and Development Strategies
12 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook by Types and Applications to 2028
-
12.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Intravenous Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Analysis and Outlook to 2028
-
13.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.2.2 Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.2.3 Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.2 UK Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.3 Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.4 Belgium Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.5 France Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.6 Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.7 Denmark Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.8 Finland Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.9 Norway Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.10 Sweden Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.11 Poland Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.12 Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.3.13 Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.2 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.3 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.4 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.8 Thailand Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.9 Singapore Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.11 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.5.2 Colombia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.5.3 Chile Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.5.4 Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.5.6 Peru Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.6.3 Oman Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.6.4 Qatar Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.7.2 South Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.7.3 Egypt Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.7.4 Algeria Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Neuromyelitis Optica Spectrum Disorder (NMOSD)
-
Figure of Neuromyelitis Optica Spectrum Disorder (NMOSD) Picture
-
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Intravenous Consumption and Growth Rate (2017-2022)
-
Figure Global Oral Consumption and Growth Rate (2017-2022)
-
Figure Global Subcutaneous Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)
-
Table North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)
-
Figure United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)
-
Figure Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure UK Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Belgium Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure France Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Denmark Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Finland Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Norway Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Sweden Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Poland Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Table APAC Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)
-
Figure China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Thailand Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Singapore Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Table South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)
-
Figure Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Colombia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Chile Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Peru Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Table GCC Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)
-
Figure Bahrain Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Oman Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Qatar Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Table Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)
-
Figure Nigeria Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure South Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Egypt Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure Algeria Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Table Oceania Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)
-
Figure Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)
-
Table Bio-Thera Solutions Company Details
-
Table Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table Bionure Company Details
-
Table Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table Boston Pharmaceuticals Company Details
-
Table Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table RemeGen Company Details
-
Table RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table Opexa Therapeutics Company Details
-
Table Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table Nihon Pharmaceutical Company Details
-
Table Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table Lundbeck Company Details
-
Table Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table Harbour BioMed Company Details
-
Table Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table TG Therapeutics Company Details
-
Table TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table Alexion Pharmaceuticals Company Details
-
Table Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table Cour Pharmaceutical Company Details
-
Table Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Table F Hoffmann-La Roche Ltd Company Details
-
Table F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Main Business and Markets Served
-
Table F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Portfolio
-
Figure Global Intravenous Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)
-
Table North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)
-
Figure United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)
-
Figure Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)
-
Figure China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)
-
Figure Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)
-
Figure Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)
-
